GSK axes Blenrep combo studies with SpringWorks` Ogsiveo
“ Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter “ “ Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid...
SpringWorks Therapeutics Announces EMA Validation for MAA of Nirogacestat
SpringWorks Announces EMA Validation for MAA of Nirogacestat
OGSIVEO Available from Onco360 as First and Only Treatment for Desmoid Tumors
Nov 28 (Reuters) - SpringWorks Therapeutics' (SWTX.O) drug for treating adult patients with a type of rare non-cancerous soft-tissue tumor will be sold in the U.S. at a list price of $29,000 for a 30-day supply, the company said on a conference call on Tuesday.
FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors
- Nirogacestat Treatment Demonstrated Rapid and Sustained Improvements in Functional Status Compared to Placebo Across Multiple Assessment Tools - STAMFORD, Conn., Nov. 01, 2023 (GLOBE NEWSWIRE)...
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting
STAMFORD, Conn., May 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients...